Ricardo Rabagliati

Dr. Ricardo Rabagliati

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
RRRicardo Rabagliati
Ricardo Rabagliati
GSGrace Salazar
Grace Salazar
GPGiancarlo Pérez-Lazo
Giancarlo Pérez-Lazo
MIMaria Paz Iturrieta
Maria Paz Iturrieta
DPDiana Portillo
Diana Portillo
PGPatricia Garcia
Patricia Garcia
Febrile neutropenia is a life-threatening condition commonly observed in patients with hematologic malignancies. The aim of this article is to provide updated knowledge about bloodstream infections in febrile neutropenia episodes within the Andean region of Latin America. This retrospective study was based in 6 hospitals in Chile, Ecuador, and Peru and included adult patients with acute leukemia or lymphoma and febrile neutropenia between January 2019 and December 2020. Of the 416 febrile neutropenia episodes, 38.7% had a bloodstream infection, 86% of which were caused by gram-negative rods, with Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa being the most frequently identified bacteria. K pneumoniae isolates were more frequently resistant than E coli to cefotaxime (65% vs 39.6%), piperacillin-tazobactam (56.7% vs 27.1%), and imipenem (35% vs 2.1%) and were more frequently multidrug resistant (61.7% vs 12.5%). Among P aeruginosa, 26.7% were resistant to ceftazidime, piperacillin-tazobactam, and imipenem, and 23.3% were multidrug resistant. Overall 30-day mortality was 19.8%, being higher with vs without a bloodstream infection (26.7% vs 15.3%, P = .005). Fever duration was also significantly longer, as well as periods of neutropenia and length of hospital stay for patients with bloodstream infection. Additionally, the 30-day mortality rate was higher for episodes with inappropriate vs appropriate empirical antibiotic therapy (41.2% vs 26.6%, P = .139). Considering the high rates of bacteria-resistant infection and 30-day mortality, it is imperative to establish strategies that reduce the frequency of bloodstream infections, increasing early identification of patients at higher risks of multidrug bacteria resistance, and updating existing empirical antibiotic recommendations.

21 December 2024 in The Brazilian Journal of Infectious Diseases
Verified
Journal Article
Open access
JCJorge Alberto Cortes
Jorge Alberto Cortes
MVMartha Carolina Valderrama-Rios
Martha Carolina Valderrama-Rios
PPPaula Pecanha
Paula Pecanha
MJMoacyr Silva Júnior
Moacyr Silva Júnior
CDCándida Diaz-Brochero
Cándida Diaz-Brochero
Arnaldo L. ColomboArnaldo L. Colombo
Arnaldo L. Colombo
Candidemia is the predominant form of invasive candidiasis and the most frequently occurring serious fungal infection in critically ill patients in Intensive Care Units (ICU). Studies carried out in Latin America reveal a higher incidence of candidemia and higher mortality rates when compared to North America or Europe. This highlights the need to develop guidelines for correctly diagnosing and treating candidemia in critically ill patients in the ICU. These guidelines are part of the efforts to implement antifungal optimization programs in the region to obtain better clinical outcomes and promote rational antifungal use. This evidence-based clinical standard, established through expert consensus for the Latin American context, contains recommendations and algorithms for diagnosing and treating candidemia in critically ill ICU patients.

31 January 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
NGNorma Urbano Gutiérrez
Norma Urbano Gutiérrez
MLMaría José Vergara López
María José Vergara López
CBCamila Álvarez Bustos
Camila Álvarez Bustos
CVCristian Contreras Vidal
Cristian Contreras Vidal
JCJorge A Carvajal
Jorge A Carvajal
MBMaría Elvira Balcells
María Elvira Balcells
Intra-amniotic infection with Candida species is an uncommon but severe condition with high fetal morbimortality and no established clinical guidelines for its management. We report a Candida albicans intra-amniotic infection diagnosed in a 25-week pregnant woman, successfully treated with high-dose liposomal amphotericin B. Pregnancy was prolonged until 30 weeks, and despite persistently positive Candida cultures in amniotic fluid, a healthy newborn was delivered without evidence of systemic infection. Amphotericin concentration was determined at birth, revealing levels over 30 times higher in mother's and cord blood than in the amniotic fluid, probably explaining the clinical protection despite failure in obtaining fungal clearance.

8 September 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RRRicardo Rabagliati
Ricardo Rabagliati
DBDona Benadof
Dona Benadof
LTLuis Thompson
Luis Thompson
PGPatricia Garcia
Patricia Garcia
TGTamara Gonzalez
Tamara Gonzalez
ONOn Behalf Of The Chilean Invasive Mycosis Network
On Behalf Of The Chilean Invasive Mycosis Network
Background: Invasive mold diseases (IMDs) are a severe complication of immunocompromised subjects and an emerging problem among severely ill, apparently immunocompetent patients. The aim of this study was to describe the epidemiological and clinical features of IMDs in Chile. Methods: Prospective study of IMD cases in children and adults from 11 reference hospitals in Chile from May 2019 to May 2021. Results: One hundred seventy-six cases were included, 135 in adults and 41 in children, with an overall incidence of 0.4/1,000 admissions. The median age was 10.5 years in children and 56.6 years in adults, with male gender predominance in adults (61.5% versus 41.5%, p = 0.03). Immunosuppression was the most common condition in both children and adults. However, cancer, neutropenia, and hematopoietic cell transplantation were significantly more frequent in the pediatric group. In contrast, diabetes, viral pneumonia, chronic kidney disease, and chronic obstructive pulmonary disease were significantly more frequent among adult patients. Regarding the diagnostic category, 30.1% of cases were proven, 55.7% probable and 14.2% possible. Aspergillosis was the most frequent IMD diagnosed in 75.5% of cases, followed by fusariosis in children and mucormycosis in adults. Viral pneumonia was associated in 40.3% of cases, mainly COVID-19, with aspergillosis in 87.3%. No triazole resistance was observed in Aspergillus spp.. Antifungals were prescribed in 97.2% of the patients: voriconazole 61.4%, liposomal amphotericin 20.5%, combination antifungals 11.1%, and others 6.4%. Overall survival was 68.7%, 61.4%, and 51.7% at 30, 90 and 180 days, respectively. Discussion: This is the most extensive study of IMDs in Chile, evidencing an incidence of 0.4 per 1,000 admissions, with aspergillosis being the most frequent infection. Nearly 40% of cases were associated with respiratory viruses, accounting for the impact of COVID-19. Despite almost all patients starting antifungal therapy, the survival rate was poor. It is advisable to start a surveillance program of IMDs in Chile and verify the absence of azole resistance of Aspergillus spp.

16 April 2026 in Microorganisms
Verified
Journal Article
Open access
PDF file
LGLarissa Simão Gandolpho
Larissa Simão Gandolpho
DADaniel Aguilar-Zapata
Daniel Aguilar-Zapata
PMPablo A Moncada
Pablo A Moncada
Fernando RieraFernando Riera
Fernando Riera
MGMariana Guarana
Mariana Guarana
Arnaldo L. ColomboArnaldo L. Colombo
Arnaldo L. Colombo
Breakthrough invasive fungal infections (bIFIs) are a challenging serious complication in high-risk hematologic patients and allogeneic hematopoietic stem cell transplantation recipients that may negatively impact their outcome. Despite advances in antifungal prophylaxis, diagnostics, and supportive care, bIFI occurrence reflects a complex interaction between host immunosuppression, emergence of resistant pathogens and pharmacological variables, including subtherapeutic drug exposure. Candida spp. have shifted towards non-albicans yeasts, whereas breakthrough mold infections more frequently involve non-fumigatus Aspergillus, Mucorales, Fusarium spp., and Scedosporium/Lomentospora spp. Early clinical recognition, rapid therapy escalation, aggressive diagnostic investigation, a switch to liposomal amphotericin B-based regimens in patients on azole prophylaxis, and therapeutic drug monitoring are essential to improve outcomes. Reducing the growing global burden of bIFIs will also require improved access to high-quality diagnostics and strengthened educational and stewardship efforts that prioritize antifungal resistance as an urgent health concern.

24 February 2025 in The Brazilian Journal of Infectious Diseases
Verified
Journal Article
Open access
JCJorge Alberto Cortes
Jorge Alberto Cortes
DRDiego Andrés Rodríguez-Lugo
Diego Andrés Rodríguez-Lugo
MVMartha Carolina Valderrama-Rios
Martha Carolina Valderrama-Rios
RRRicardo Rabagliati
Ricardo Rabagliati
DCDomenico Capone
Domenico Capone
MNMarcio Nucci
Marcio Nucci
Aspergillosis is a disease caused by the filamentous fungus Aspergillus spp. with a spectrum of clinical presentation that includes invasive and noninvasive forms. The invasive clinical presentation of aspergillosis most frequently affects people with compromised immune systems. In patients with oncohematologic pathology, invasive lung aspergillosis is a significant opportunistic mycosis, because it occurs frequently and has a major impact on morbidity, mortality, and high costs. The global problem of antimicrobial resistance, to which improper use of antifungals contributes, has put Aspergilus spp. in the spotlight, so it is important to generate guidelines for guidance in the proper use of antifungals in the management of invasive lung aspergillosis, to obtain better clinical outcomes and promote rational use of antifungals. This guideline contains recommendations for diagnosing and treating invasive lung aspergillosis in patients with oncohematologic disease, based on evidence and defined through a participatory process of expert consensus, for the Latin American context.